Phase II study of high-dose medroxyprogesterone acetate in advanced malignant melanoma. 1989

R Becher, and O Kloke, and K Höffken, and M E Scheulen, and U B Wandl, and H Bojar, and C G Schmidt
Innere Klinik und Poliklinik (Tumorforschung), Westdeutsches Tumorzentrum, Essen, Federal Republic of Germany.

UI MeSH Term Description Entries
D008525 Medroxyprogesterone A synthetic progestational hormone used in veterinary practice as an estrus regulator. (6 alpha)-17-Hydroxy-6-methylpregn-4-ene-3,20-dione,Methylhydroxyprogesterone,Pregn-4-ene-3,20-dione, 17-hydroxy-6-methyl-, (6alpha)-,17 alpha-Hydroxy-6 alpha-Methylprogesterone,Adgyn Medro,17 alpha Hydroxy 6 alpha Methylprogesterone
D008545 Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) Malignant Melanoma,Malignant Melanomas,Melanoma, Malignant,Melanomas,Melanomas, Malignant
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D017258 Medroxyprogesterone Acetate A synthetic progestin that is derived from 17-hydroxyprogesterone. It is a long-acting contraceptive that is effective both orally or by intramuscular injection and has also been used to treat breast and endometrial neoplasms. Depo-Medroxyprogesterone Acetate,Medroxyprogesterone 17-Acetate,Pregn-4-ene-3,20-dione, 17-(acetyloxy)-6-methyl-, (6alpha)-,(6 alpha)-17-(Acetoxy)-6-methylpregn-4-ene-3,20-dione,6-alpha-Methyl-17alpha-hydroxyprogesterone Acetate,Curretab,Cycrin,Depo-Provera,Farlutal,Gestapuran,Medroxyprogesterone 17-Acetate, (6 alpha,17 alpha)-Isomer,Medroxyprogesterone 17-Acetate, (6 beta)-Isomer,Perlutex,Provera,Veramix,6 alpha Methyl 17alpha hydroxyprogesterone Acetate,Depo Medroxyprogesterone Acetate,Depo Provera,DepoProvera,Medroxyprogesterone 17 Acetate

Related Publications

R Becher, and O Kloke, and K Höffken, and M E Scheulen, and U B Wandl, and H Bojar, and C G Schmidt
May 1982, Cancer treatment reports,
R Becher, and O Kloke, and K Höffken, and M E Scheulen, and U B Wandl, and H Bojar, and C G Schmidt
January 1983, Cancer chemotherapy and pharmacology,
R Becher, and O Kloke, and K Höffken, and M E Scheulen, and U B Wandl, and H Bojar, and C G Schmidt
February 1982, Cancer treatment reports,
R Becher, and O Kloke, and K Höffken, and M E Scheulen, and U B Wandl, and H Bojar, and C G Schmidt
January 1978, Acta radiologica: oncology, radiation, physics, biology,
R Becher, and O Kloke, and K Höffken, and M E Scheulen, and U B Wandl, and H Bojar, and C G Schmidt
January 1979, Cancer treatment reports,
R Becher, and O Kloke, and K Höffken, and M E Scheulen, and U B Wandl, and H Bojar, and C G Schmidt
October 1986, Gan to kagaku ryoho. Cancer & chemotherapy,
R Becher, and O Kloke, and K Höffken, and M E Scheulen, and U B Wandl, and H Bojar, and C G Schmidt
October 1983, Cancer treatment reports,
R Becher, and O Kloke, and K Höffken, and M E Scheulen, and U B Wandl, and H Bojar, and C G Schmidt
September 1982, Cancer treatment reports,
R Becher, and O Kloke, and K Höffken, and M E Scheulen, and U B Wandl, and H Bojar, and C G Schmidt
September 1982, Cancer treatment reports,
R Becher, and O Kloke, and K Höffken, and M E Scheulen, and U B Wandl, and H Bojar, and C G Schmidt
January 1984, Investigational new drugs,
Copied contents to your clipboard!